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gests that though oncologists use economic tools in their
choice of therapy, the extent of use is lower than ex-
pected; and the choice of therapy varied more with the
first and third lines of therapy.
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Colorectal cancer (CRC), the second leading cause of
cancer deaths in the US, can be detected in its early
stages. Detection and removal of adenomas can prevent
CRC. Early detection of CRC by screening asymptomatic
populations with fecal occult blood tests (FOBTs) can
significantly reduce mortality and morbidity. OBJEC-
TIVE: The purpose of this analysis was to measure out-
comes when FOBTs are used as the primary screening
tools. METHODS: A cost-effectiveness model was devel-
oped for 10 years of annual serial screening. Assumptions
for the fixed cohort population were for an initial popu-
lation of 100,000 with 0.33% prevalence of CRC,
5.64% prevalence of adenomas (1 cm), 2.91% annual
conversion rate of adenomas to CRC, and an annual inci-
dence rate for adenomas of 0.31%. Two FOBTs were
evaluated in this analysis: Hemoccult (HO), and Hemoc-
cult SENSA (HOS). A decision-analytic model was used
to evaluate testing modalities, test positivity rates, pro-
gram compliance, treatment options and surveillance reg-
imens. Test performance statistics were obtained from
published clinical trials and related healthcare data. RE-
SULTS: Summary of Model Outcomes Compared to a
No Testing Scenario:
CONCLUSION: Cost-effective screening of asymptom-
atic populations can be achieved with either FOBT. HOS,
however, has better sensitivity than HO in detecting ade-
nomas and CRC. This results in greater prevention of
CRC and lower treatment and terminal care costs that fa-
vorably impact the $/LYG estimate.
FOBT
Adenomas
Detected
CRC
Prevented
CRC Deaths
Prevented
$ (000)/Life Year
Gained (LYG)
HO 2,016 304 193 $32
HOS 3,439 603 303 $25
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Hereditary non-polyposis colorectal cancer (HNPCC) is
a cancer susceptibility syndrome characterized by in-
creased risk for colorectal cancer (CRC). Genetic testing
for HNPCC can risk-stratify family members. Those
lacking inherited susceptibility can avoid costly and fre-
quent colonoscopic surveillance. OBJECTIVE: Evaluate
the cost-effectiveness of a genetic testing strategy for a
family member at risk for inheriting susceptibility to
HNPCC-related CRC. METHODS: A decision analytic
model simulated health and economic outcomes. A hypo-
thetical cohort of 20 year-old consultants from HNPCC
kindreds progressed through the model. We assumed that
surveillance prevents CRC, and that patients averaged a
life expectancy of 80 years. The genetic testing strategy
included relevant mutation analysis with and without
screening a family member’s tumor tissue for microsatel-
lite instability (MSI) and immunohistochemical (IHC)
staining for the MLH1 and MSH2 gene products. Pa-
tients testing negative for a familial mutation underwent
surveillance as recommended by the American Cancer
Society, and those positive as recommended by the Inter-
national Collaborative Group for high-risk patients.
Probability estimates were derived from a systematic re-
view of the MEDLINE and HEALTSTAR databases.
Cost estimates were derived from the Medicare 1999
Physician Fee Schedule—Area 18. Sensitivity analyses
were performed on all estimates. The outcome was cost-
per-strategy to prevent CRC. RESULTS: The genetic test-
ing strategy yielded an average savings of $869.73 per
patient. Its cost-effectiveness persisted over a wide range
of probability and cost variables. The genetic testing
strategy resulted in 67% fewer invasive, endoscopic pro-
cedures. CONCLUSION: Both costs and procedures for
CRC surveillance and prevention are substantially re-
duced for at-risk individuals from an HNPCC kindred
who participate in a strategy that begins with genetic
testing.
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Low Grade Non-Hodgkin’s Lymphoma (LGNHL) is an
indolent form of NHL with a median survival of four to
eleven years. This survival is dependent on the respon-
